Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HMA-Venetoclax Induction in Young, Fit Patients With Newly Diagnosed AML
NCT07748455Phase 2
Key facts
- Status
- Not yet recruiting
- Start
- Aug 2026
- Primary completion
- Dec 2027
- Countries
- 1
- Sponsor
- Pakistan Blood and Marrow Transplant Group
- Conditions
- acute myeloid leukemia (AML)
01
Overview
Phase 2, open-label, single-arm trial of venetoclax and azacitidine in acute myeloid leukemia (AML), sponsored by Pakistan Blood and Marrow Transplant Group. Primary endpoint: Remission rate. Planned start Aug 2026; status: not yet recruiting.
02
Design
1 arm- Study design
- Non-randomizedOpen-labelSingle group
Aza-Ven Arm
Azacitidine + Venetoclax induction for up to 2 cycles
03
Who it enrols
Young, fit patients (18-50 years) with newly diagnosed AML (non-APL), ECOG 0-2, adequate organ function, and no prior AML therapy.
04
Endpoints
Primary
Remission rate
Secondary
Event-Free Survival
Overall Survival
Measurable Residual Disease
Hematopoietic Stem Cell Transplant conversion rate
Beyond the preview
Go deeper on NCT07748455.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07748455.